Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
- Mar 5, 2024
- 2 min read
This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials.
WALTHAM, Mass., March 5, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a solid tumor targeting TriNKET®.
ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly's platform technology to enter the clinic, and the first AbbVie-licensed TriNKET® drug candidate to enter into the clinic. The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie's budigalimab (ABBV-181), in solid tumors.
"We are delighted that AbbVie has advanced ABBV-303 into the clinic," said Bill Haney, CEO and Dragonfly co-founder. "AbbVie is a global leader in advancing novel treatments for some of the most complex diseases and a terrific partner. We look forward to continued success and rapid progress with the AbbVie team to advance potential new treatment options for patients."
Additional information about the M24-122 Phase 1 trial, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT06158958).
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing novel therapies that harness the body's immune system to bring breakthrough treatments to patients. In addition to a set of advanced programs in the clinic, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platforms that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit:www.dragonflytx.comhttps://www.linkedin.com/company/dragonfly-therapeutics-inc./https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne E. Deconinck | anne@dragonflytx.com
SOURCE Dragonfly Therapeutics, Inc.
WPL 관련 정리된 사이트 참고했습니다.
https://wpl.clickn.co.kr
Mình có lần lướt đọc mấy trao đổi trên mạng شيخ روحاني thì thấy nhắc nên cũng tò mò mở ra xem thử cho biết. Mình không tìm hiểu sâu rauhane chỉ xem qua trong thời gian ngắn để quan sát bố cục s3udy cách sắp xếp các mục và trình bày nội dung tổng thể. Cảm giác là các phần được trình bày khá gọn, các mục rõ ràng nên đọc lướt cũng không bị rối Berlinintim, với mình như vậy là đủ để nắm tin cơ bản rồi. q8yat
I think the Rice Purity Test highlights how society often tries to quantify experiences. While it’s entertaining, it’s also a reminder that life isn’t a checklist. People grow at different paces, and what matters most is making choices that align with personal values rather than comparing oneself to others.
This is a significant milestone — early-phase trials like this are where safety and initial effectiveness are tested, so dosing the first patient is a crucial step in moving a therapy forward. It’s impressive to see how collaborations like this aim to develop new immunotherapies targeting solid tumors, especially using advanced platforms like TriNKET® . Progress at this stage depends heavily on careful research, coordination, and long-term commitment. That idea of how structured effort and external expectations influence outcomes also connects more broadly to discussions by Mārtiņš Lauva , where awareness and pressure play a role in shaping results in a completely different field.
Doing thorough research is always important, and I found contenc to be a helpful resource with detailed information on related topics worth reading.